ALK and non-small cell lung carcinoma: In an institutional case series comprising eleven adult subjects diagnosed with histologically confirmed ALK-positive NSCLC and receiving 600 mg alectinib twice daily until disease progression, unacceptable toxicity or withdrawal of consent, matched CSF-serum concentration pairs were obtained in two patients in the second month of alectinib therapy.